LAVA Therapeutics N.V. (LVTX)

LAVA Therapeutics Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	44.23	100.33	90.87	15.82	7.34
Short-Term Investments	51.34	32.54	42.33	0	0
Cash & Cash Equivalents	95.57	132.87	133.2	15.82	7.34
Cash Growth	-28.07%	-0.25%	742.10%	115.56%	-
Receivables	1.46	3.25	0.36	1.14	0.07
Other Current Assets	1.87	4.41	2.94	1.26	0.21
Total Current Assets	98.9	140.53	136.51	18.22	7.62
Property, Plant & Equipment	2.49	2.08	1.95	1.5	1.15
Other Long-Term Assets	0.32	0.81	0.8	0.77	0.03
Total Long-Term Assets	2.81	2.89	2.74	2.26	1.18
Total Assets	101.71	143.43	139.25	20.49	8.8
Accounts Payable	4.45	3.97	2.55	0.93	0.42
Deferred Revenue	35	35	1.53	6.18	0
Current Debt	5.72	5.02	0.26	0.21	0.24
Other Current Liabilities	-30.23	-22.03	6.91	0.02	0.77
Total Current Liabilities	14.94	21.95	11.25	7.34	1.42
Long-Term Debt	0.59	0.43	4.6	3.88	1.53
Other Long-Term Liabilities	35	35	5.03	1.66	0
Total Long-Term Liabilities	35.59	35.43	9.63	5.53	1.53
Total Liabilities	50.53	57.39	20.88	12.87	2.95
Total Debt	6.31	5.45	4.87	4.08	1.77
Debt Growth	15.83%	12.02%	19.18%	131.27%	-
Retained Earnings	-148.07	-108.07	-76.16	-33.39	-13.7
Comprehensive Income	-10.9	-12.97	-6.22	-1	-0.38
Shareholders' Equity	51.18	86.04	118.37	7.62	5.84
Net Cash / Debt	89.26	127.42	128.34	11.74	5.57
Net Cash / Debt Growth	-29.95%	-0.72%	993.54%	110.59%	-
Net Cash Per Share	3.34	4.92	6.50	29.40	12.45
Working Capital	83.96	118.58	125.26	10.89	6.2
Book Value Per Share	1.91	3.32	5.99	19.09	13.06

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).